Annual report pursuant to Section 13 and 15(d)

Note 11 - Shareholders' Equity

v3.20.4
Note 11 - Shareholders' Equity
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]
11.
Shareholders
'
Equity
 
Authorized capital stock
 
DiaMedica has authorized share capital of an unlimited number of common voting shares and the shares do
not
have a stated par value.
 
Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to
one
vote per share at the Company's annual general meeting and any extraordinary general meeting.
 
Equity issued during the year ended
December 31, 2020
 
On
August 10, 2020,
the Company issued and sold an aggregate of
4,600,000
common shares in an initial public offering at a price to the public of
$5.00
per share. As a result of the offering, the Company received gross proceeds of
$23.0
million, which resulted in net proceeds to the Company of approximately
$21.1
 million, after deducting the underwriting discount and offering expenses.
 
On
February 13, 2020,
the Company issued and sold an aggregate of
2,125,000
common shares in an initial public offering at a price to the public of
$4.00
per share. As a result of the offering, the Company received gross proceeds of
$8.5
million, which resulted in net proceeds to the Company of approximately
$7.7
 million, after deducting the underwriting discount and offering expenses.
 
During the year ended
December 31, 2020,
14,283
common shares were issued upon the exercise of options for gross proceeds of
$45,161
and
no
warrants were exercised.
 
Equity issued during the year ended
December 31, 2019
 
During the year ended
December 31, 2019,
50,000
common shares were issued upon the exercise of options for gross proceeds of
$75,000
and
no
warrants were exercised.
 
Shares reserved
 
Common shares reserved for future issuance are as follows:
 
   
December 31, 2020
  
Employee and non-employee stock options
    
1,389,564
  
Common shares issuable upon settlement of deferred share units
    
47,237
  
Shares available for grant under the 2019 Omnibus Incentive Plan
    
1,099,098
  
Common shares issuable under common share purchase warrants
    
265,000
  
Total
    
2,800,899